Am Fam Physician. 2024;109(4):310-311
Author disclosure: No relevant financial relationships.
Details for This Review
Study Population: 36 studies with 23,299 women in two main groups: early menopausal women (fewer than 5 years since amenorrhea or menopause) with or without menopausal symptoms and “unselected” postmenopausal women (last menstrual period more than 5 years earlier, regardless of menopausal symptoms)
Efficacy End Points: Primary: sexual-function composite score; secondary: domains of sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain
Harm End Points: Not evaluated in this review
| Benefits |
| Slight improvement in sexual-function composite score for estrogen alone compared with placebo or no intervention (standardized mean difference = 0.50; 95% CI, 0.04 to 0.96) in women experiencing early postmenopause (< 5 years since amenorrhea) or experiencing other symptoms due to menopause |
| Slight improvement in sexual-function composite score for selective estrogen-receptor modulators compared with placebo or no intervention (mean difference = 2.24; 95% CI, 1.37 to 3.11) in unselected postmenopausal women |
| Harms |
| Not evaluated |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
